US Pharma MarketingThe post Verrica completes enrolment in Phase III trial of Ycanth appeared first on Clinical Trials Arena.
Verrica completes enrolment in Phase III trial of Ycanth
Verrica Pharmaceuticals has completed patient enrolment in its first pivotal Phase III trial, COVE-2, evaluating Ycanth as a treatment for common warts. The COVE-2 trial follows a previously completed Phase II trial that had shown a decline in the number of common warts. The COVE-2 study is the first of two double-blind, vehicle-controlled, randomised trial assessing the safety and efficacy of VP-102/TO-208. Credit: PaeGAG / Shutterstock.com. Verrica Pharmaceuticals has completed patient enrolment in its first pivotal Phase III trial, COVE-2, which is part of a global clinical programme evaluating Ycanth (VP-102), to treat common warts. Top line data from the…
Verrica Pharmaceuticals has completed patient enrolment in its first pivotal Phase III trial, COVE-2, evaluating Ycanth as a treatment for common warts.
Source: Clinical Trials Arena